• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Rafael Holdings, Inc. Class B Common Stock (NY:RFL)

    1.322 +0.002 (+0.14%)
    Streaming Delayed Price Updated: 9:31 AM EDT, May 27, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Press Releases about Rafael Holdings, Inc. Class B Common Stock

    < Previous 1 2 Next >
    News headline image
    Rafael Holdings Announces Patent Licensing Agreement with MIT for “Small Molecules to Improve Myelination in ApoE4 positive Alzheimer’s Disease”
    License of the MIT patent strengthens Rafael’s intellectual property around cyclodextrins as an Active Pharmaceutical Ingredient (API) in the treatment of ApoE4-positive Alzheimer’s Disease 
    From Rafael Holdings, Inc.
    Via GlobeNewswire
    News headline image
    Rafael Holdings Reports Second Quarter Fiscal 2026 Financial Results
    From Rafael Holdings, Inc.
    Via GlobeNewswire
    News headline image
    Rafael Holdings Reports First Quarter Fiscal 2026 Financial Results
    From Rafael Holdings, Inc.
    Via GlobeNewswire
    News headline image
    Rafael Holdings Reports Fourth Quarter and Full Year Fiscal 2025 Financial Results
    From Rafael Holdings, Inc.
    Via GlobeNewswire
    News headline image
    Rafael Holdings Mourns the Passing of Lead Independent Director, Stephen Greenberg, and Announces the Appointment of Alan Grayson to its Board of Directors
    From Rafael Holdings, Inc.
    Via GlobeNewswire
    News headline image
    Rafael Holdings Announces Presentation of Preliminary Data from Ongoing Phase 3 TransportNPC™ Open-Label, Single-Arm Sub-Study in Patients Less Than 3 Years Old
    From Rafael Holdings, Inc.
    Via GlobeNewswire
    News headline image
    Rafael Holdings Announces Abstracts Accepted for Oral and Poster Presentations at the 15th International Congress of Inborn Errors of Metabolism (ICIEM)
    From Rafael Holdings, Inc.
    Via GlobeNewswire
    News headline image
    Rafael Holdings Announces Continuation of its Phase 3 Study for the Treatment of Niemann-Pick Disease Type C1 (NPC1) Following Independent Data Monitoring Committee (DMC) Review of Prespecified 48-Week Interim Data
    From Rafael Holdings, Inc.
    Via GlobeNewswire
    News headline image
    Rafael Holdings Reports Third Quarter Fiscal 2025 Financial Results
    Cyclo Therapeutics’ TransportNPC™ Phase 3 clinical trial for Trappsol® Cyclo™ for the treatment of Niemann-Pick Disease Type C1, a rare and fatal genetic disease, is fully enrolled and results from the... 
    From Rafael Holdings, Inc.
    Via GlobeNewswire
    News headline image
    Rafael Holdings, Inc. Announces Final Results and Closing of Rights Offering
    From Rafael Holdings, Inc.
    Via GlobeNewswire
    News headline image
    Rafael Holdings, Inc. Provides Update to the Description of Subscription Rights Related to its Public Warrants in Connection With its Previously Announced $25 Million Rights Offering to Support Its Commitment to the Development and Potential Launch of
    From Rafael Holdings, Inc.
    Via GlobeNewswire
    News headline image
    Rafael Holdings, Inc. Announces Revised Subscription Rights in Connection With its Previously Announced $25 Million Rights Offering to Support Its Commitment to the Development and Potential Launch of Trappsol® Cyclo™
    From Rafael Holdings, Inc.
    Via GlobeNewswire
    News headline image
    Rafael Holdings, Inc. Announces Proposed Terms of a $25 Million Rights Offering to Support Its Commitment to the Development and Potential Launch of Trappsol® Cyclo™
    From Rafael Holdings, Inc.
    Via GlobeNewswire
    News headline image
    Rafael Holdings Strengthens its Focus on the Development of Trappsol® Cyclo™ and Announces Chief Executive Officer Bill Conkling Will Be Stepping Down from His Role
    From Rafael Holdings, Inc.
    Via GlobeNewswire
    News headline image
    Rafael Holdings Completes Merger with Cyclo Therapeutics Following Shareholder Approvals
    Cyclo Therapeutics’ TransportNPC™ Phase 3 clinical trial for Trappsol® Cyclo™ for the treatment of Niemann-Pick Disease Type C1, a rare and fatal genetic disease, is fully enrolled and results from the... 
    From Rafael Holdings, Inc.
    Via GlobeNewswire
    News headline image
    Rafael Holdings Reports Second Quarter Fiscal 2025 Financial Results
    From Rafael Holdings, Inc.
    Via GlobeNewswire
    News headline image
    Rafael Holdings Reports First Quarter Fiscal 2025 Financial Results
    Upon completion of our proposed merger with Cyclo Therapeutics the Company intends to focus its efforts on Cyclo’s lead clinical program Trappsol® Cyclo™ 
    From Rafael Holdings, Inc.
    Via GlobeNewswire
    News headline image
    Rafael Holdings Reports Fourth Quarter and Full Year Fiscal 2024 Financial Results
    Our proposed merger with Cyclo Therapeutics advances our strategy to invest in, develop and commercialize clinical stage assets which address areas of high unmet medical need 
    From Rafael Holdings, Inc.
    Via GlobeNewswire
    News headline image
    SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates CDE, SMC, COFS, RFL on Behalf of Shareholders
    From Halper Sadeh LLC
    Via GlobeNewswire
    News headline image
    SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates BTTR, RVNC, ARC, RFL on Behalf of Shareholders
    From Halper Sadeh LLC
    Via GlobeNewswire
    News headline image
    SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates COFS, ARC, NBY, RFL on Behalf of Shareholders
    From Halper Sadeh LLC
    Via GlobeNewswire
    News headline image
    BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: CrossFirst Bankshares, Inc. (Nasdaq - CFB), Arch Resources, Inc. (NYSE - ARCH), Cyclo Therapeutics, Inc. (Nasdaq - CYTH), Vector Group Ltd. (NYSE - VGR)
    From Brodsky & Smith LLC
    Via GlobeNewswire
    News headline image
    BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: CrossFirst Bankshares, Inc. (Nasdaq - CFB), Arch Resources, Inc. (NYSE - ARCH), Cyclo Therapeutics, Inc. (Nasdaq - CYTH), Vector Group Ltd. (NYSE - VGR)
    From Brodsky & Smith LLC
    Via GlobeNewswire
    News headline image
    RFL Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Rafael Holdings, Inc. Is Fair to Shareholders
    From Halper Sadeh LLC
    Via Business Wire
    News headline image
    Rafael Holdings and Cyclo Therapeutics Enter Into a Definitive Merger Agreement
    From Cyclo Therapeutics, Inc.
    Via Business Wire
    News headline image
    Rafael Holdings and Cyclo Therapeutics Enter into a Definitive Merger Agreement
    From Rafael Holdings, Inc.; Cyclo Therapeutics
    Via GlobeNewswire
    News headline image
    Rafael Holdings Reports Third Quarter Fiscal 2024 Financial Results
    Strategically focused on generating shareholder value by advancing our portfolio and identifying attractive investment opportunities with substantive upside potential 
    From Rafael Holdings, Inc.
    Via GlobeNewswire
    News headline image
    Cyclo Therapeutics Achieves Landmark Milestone with Completion of Enrollment of Last Patient in Phase 3 Pivotal TransportNPC™ Trial of Niemann-Pick Type C1
    From Cyclo Therapeutics, Inc.
    Via Business Wire
    News headline image
    Rafael Holdings Reports Second Quarter Fiscal 2024 Financial Results
    From Rafael Holdings, Inc.
    Via GlobeNewswire
    News headline image
    Rafael Holdings Reports First Quarter Fiscal 2024 Financial Results
    Company remains focused on generating shareholder value by advancing our portfolio and identifying attractive opportunities for strategic investments 
    From Rafael Holdings, Inc.
    Via GlobeNewswire
    < Previous 1 2 Next >
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.